Atropine Sulfate
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Atropine Sulfate
- Generic name
- ATROPINE SULFATE
- Manufacturer
- Lifestar Pharma LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- b5f78b2a-56d1-4400-9d2f-b033cc13d26e
- SPL ID
- 3d2f2743-d245-4a85-b6cb-e4e7cc417394
- Version
- 4
- Effective date
- 2025-10-13
- Source export date
- 2026-09-28
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/663999d0fe1757c1e2cd13a4799d76d875f663e0bc57701092264ebe7febfc18/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:26:24
| Harmonized routes |
|---|
| OPHTHALMIC |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 218148 | derived:openfda.application_number |
| application number | ANDA218148 | openfda.application_number | |
| brand name | Atropine Sulfate | openfda.brand_name | |
| generic name | ATROPINE SULFATE | openfda.generic_name | |
| manufacturer name | Lifestar Pharma LLC | openfda.manufacturer_name | |
| ndc | package | 70756-651-25 | openfda.package_ndc |
| ndc | package | 70756-652-25 | openfda.package_ndc |
| ndc | package | 70756-653-35 | openfda.package_ndc |
| ndc | product | 70756-651 | openfda.product_ndc |
| ndc | product | 70756-652 | openfda.product_ndc |
| ndc | product | 70756-653 | openfda.product_ndc |
| ndc11 | package | 70756065335 | derived:openfda.package_ndc |
| ndc11 | package | 70756065225 | derived:openfda.package_ndc |
| ndc11 | package | 70756065125 | derived:openfda.package_ndc |
| rxcui | 1190655 | openfda.rxcui | |
| spl id | 3d2f2743-d245-4a85-b6cb-e4e7cc417394 | id | |
| spl set id | b5f78b2a-56d1-4400-9d2f-b033cc13d26e | set_id | |
| unii | 03J5ZE7KA5 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks. (5.1) Risk of blood pressure increase from systemic absorption. (5.2) 5.1 Photophobia and Blurred Vision Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks. 5.2 Elevation of Blood Pressure Elevations in blood pressure from systemic absorption has been reported following conjunctival instillation of recommended doses of Atropine Sulfate Ophthalmic Solution, 1%. 5.3 Risk of Contamination Do not touch the dropper tip to the eye, eyelids, or any other surface as this may contaminate the solution.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Photophobia and Blurred Vision [See Warnings and Precautions (5.1)] Elevation in Blood Pressure [See Warnings and Precautions (5.2)] The following adverse reactions were identified in clinical studies or postmarketing reports following use of atropine sulfate ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Most common adverse reactions that have been reported are eye pain and stinging on administration, blurred vision, photophobia, decreased lacrimation, increased heart rate and blood pressure. To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Ocular Adverse Reactions Eye pain and stinging occurs upon instillation. Other commonly occurring adverse reactions include, blurred vision, photophobia, superficial keratitis and decreased lacrimation. Allergic reactions such as papillary conjunctivitis, contact dermatitis, and lid edema may also occur less commonly. 6.2 Systemic Adverse Reactions Systemic effects of atropine are related to its anti-muscarinic activity. Systemic adverse events reported include dryness of skin, mouth, and throat from decreased secretions from mucus membranes; restlessness, irritability or delirium from stimulation of the central nervous system; tachycardia; flushed skin of the face and neck.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.